Table 5.

Summary of IFN-free direct-acting antivirals for acute HCV infection after solid organ transplantation from HCV-viremic donors to HCV-aviremic recipients

Study (year)		Regimen	Duration (week)	Strategy	Patient, n	HCV GT	SVR12 (%) (ITT)	SVR12 (%) (PP)
Heart
	USHER (2019) [126]	EBR/GZR	12	Pre-emptive	10	1	90*	100
	Bethea et al. (2019) [127]	GLE/PIB	8	Pre-emptive	25	1–3, indeterminate, NA	100	100
	Reyentovich et al. (2020) [128]	GLE/PIB	8	Pre-emptive	22	NA	100	100
	Smith et al. (2021) [129]	GLE/PIB	8	Pre-emptive	22	1–3, indeterminate	100	100
	DONATE-HCV (2019) [130]	SOF/VEL	4	Pre-emptive	8	1–3, indeterminate	100†	100†
Lung
	Smith et al. (2021) [129]	GLE/PIB	8	Prophylactic/pre-emptive	16	1–3, indeterminate	100	100
	DONATE-HCV (2019) [130]	SOF/VEL	4	Pre-emptive	36	1–3, indeterminate	100‡	100‡
	Cypel et al. (2020) [131]	SOF/VEL	12	Deferred	20	1–3	90	90
Liver
	Bethea et al. (2020) [132]	GLE/PIB	12	Pre-emptive	9	1–3	100	100
	Terrault et al. (2021) [133]	SOF/VEL	12	Pre-emptive	13	NA	100	100
	Kwong et al. (2018) [134]	SOF/LDV, SOF/DCV, or SOF/VEL±RBV	12-24	Deferred	10	1–3	100	100
Kidney
	THINKER-1 (2017) [135]	EBR/GZR	12	Pre-emptive	10	1	100	100
		EBR/GZR+RBV	16			1 (NS5A RAS)
	THINKER-2 (2018) [136]	EBR/GZR	12	Pre-emptive	10	1	100	100
		EBR/GZR+RBV	16			1 (NA5A RAS)
	EXPANDER (2018) [137]	EBR/GZR	12	Prophylactic	10	1a, 1b, 4, indeterminate GT due to low viral load	100	100
		EBR/GZR+RBV	16			1a (NA5A RAS)
		EBR/GZR+SOF	12			2, 3
	REHANNA (2021) [138]	GLE/PIB	4	Prophylactic	10	1, 3	100	100
	MYTHIC (2020) [139]	GLE/PIB	8	Pre-emptive	30	1, 2, 4	88	88
	DAPPeR (2021) [140]	SOF/VEL	2–4 days	Prophylactic	50	1–3	97	97
	REFORM HEPC (2021) [141]	SOF/VEL	8 days	Prophylactic	32	NA	94	94
		SOF/VEL+ezetimibe			18
	Terrault et al. (2021) [133]	SOF/VEL	12	Pre-emptive	11	NA	100	100
Miscellaneous (heart, lung, kidney, and kidney-pancreas)
	Feld et al. (2020) [142]	GLE/PIB+ezetimibe	1	Prophylactic	18	1–3	100	100

IFN, interferon; HCV, hepatitis C virus; GT, genotype; SVR12, sustained virologic response at off-therapy week 12; ITT, intention-to-treat; PP, per-protocol; EBR, elbasvir; GZR, grazoprevir; GLE, glecaprevir; PIB, pibrentasvir; NA, not assessed; SOF, sofosbuvir; VEL, velpatasvir; LDV, ledipasvir; DCV, daclatasvir; RBV, ribavirin; NS5A, non-structural protein 5A; RAS, resistanceassociated substitution.

^*Died on post-transplantation Day 79 due to antibody-mediated rejection and multi-organ failure.

^†One of the 8 patients was pending SVR12 result at the time of publication.

^‡Eight of the 36 patients were pending SVR12 results at the time of publication.